Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives

Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors

(2015) Ken Saijo et al.   CANCER SCIENCE

Panobinostat for the Treatment of Multiple Myeloma

(2015) J. P. Laubach et al.   CLINICAL CANCER RESEARCH

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma

(2015) Song Mu et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors

(2015) Marina Savelieva et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

(2015) Madhusoodanan Mottamal et al.   MOLECULES

A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function

(2014) Sunil Sharma et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function

(2014) Marije Slingerland et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Belinostat: First Global Approval

(2014) Raewyn M. Poole   DRUGS

Polypharmacy in Patients With Advanced Cancer and Pain: A European Cross-Sectional Study of 2282 Patients

(2014) Aleksandra Kotlinska-Lemieszek et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Prevalence and factors associated with polypharmacy in older people with cancer

(2014) Justin P. Turner et al.   SUPPORTIVE CARE IN CANCER

Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment

(2014) De-Si Pan et al.   MedChemComm

A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer

(2013) Ronald Feld et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors

(2013) Sunil Sharma et al.   INVESTIGATIONAL NEW DRUGS

Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma

(2013) Jesús F. San-Miguel et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

(2013) D J DeAngelo et al.   LEUKEMIA

Inhibition of Plk1 and Cyclin B1 Expression Results in Panobinostat-Induced G2 Delay and Mitotic Defects

(2013) Michael Prystowsky et al.   Scientific Reports

Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients

(2012) Sally Clive et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Panobinostat for the treatment of multiple myeloma

(2012) Paola Neri et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

(2012) Akira Fukutomi et al.   INVESTIGATIONAL NEW DRUGS

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

(2011) Geoffrey I. Shapiro et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

(2011) Paul Hamberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

(2011) Sachi Morita et al.   INVESTIGATIONAL NEW DRUGS

Clinical development of panobinostat in classical Hodgkin’s lymphoma

(2011) Yasuhiro Oki et al.   Expert Review of Hematology

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

(2010) Dana Rathkopf et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The role of histone deacetylases in prostate cancer

(2010) Ata Abbas et al.   Epigenetics

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of vorinostat: Current applications and future perspectives for cancer therapy

(2009) Victoria M. Richon et al.   CANCER LETTERS

Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression

(2009) J. Suzuki et al.   CLINICAL CANCER RESEARCH

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

(2009) H Miles Prince et al.   Future Oncology

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors in lymphoma and solid malignancies

(2008) Walid Rasheed et al.   Expert Review of Anticancer Therapy

An Inactivating Mutation in HDAC2 Leads to Dysregulation of Apoptosis Mediated by APAF1

(2008) Christin L. Hanigan et al.   GASTROENTEROLOGY

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

(2008) L Marquard et al.   HISTOPATHOLOGY

HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21

(2008) Andrew J. Wilson et al.   MOLECULAR BIOLOGY OF THE CELL